Curis Inc (CRIS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.97M
Last updated: Nov 17, 2026 at 11:04 AM ET
Curis Inc (CRIS) Earnings: Report Dates and Results
Curis (CRIS) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Curis reported EPS of -$1.94, above the -$2.29 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CRIS has an expected report date of Mar 17, 2027.
CRIS Earnings Call
The latest CRIS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 38 quarters below that had an estimate, CRIS beat 20, missed 17 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2026, when EPS landed 331.03% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.94 | -$2.29 | -$2.29 - -$1.73 | +15.28% | Beat | N/A | 2 | 1 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$4.02 | -$5.70 | -$5.70 - -$4.40 | +29.47% | Beat | N/A | 3 | 2 up, 0 down | Aug 14, 2026 | N/A |
| Mar 31, 2026 | -$25.00 | -$5.80 | -$7.80 - -$3.80 | -331.03% | Miss | N/A | 2 | 0 up, 0 down | May 12, 2026 | N/A |
| Dec 31, 2025 | -$9.95 | -$8.65 | -$14.40 - -$5.60 | -15.01% | Miss | N/A | 4 | 0 up, 1 down | Mar 19, 2026 | $1.14M |
| Sep 30, 2025 | -$9.80 | -$12.00 | -$14.80 - -$11.00 | +18.33% | Beat | N/A | 4 | 1 up, 1 down | Nov 6, 2025 | $3.18M |
| Jun 30, 2025 | -$13.60 | -$30.30 | -$64.80 - -$16.20 | +55.12% | Beat | N/A | 4 | 1 up, 0 down | Aug 5, 2025 | $2.75M |
| Mar 31, 2025 | -$25.00 | -$25.27 | -$27.80 - -$23.60 | +1.07% | Beat | N/A | 3 | 1 up, 0 down | May 6, 2025 | $2.38M |
| Dec 31, 2024 | -$1.25 | -$0.99 | N/A | -26.26% | Miss | N/A | 3 | 2 up, 0 down | Mar 31, 2025 | $3.35M |
| Sep 30, 2024 | -$34.00 | -$38.16 | -$42.20 - -$32.80 | +10.90% | Beat | N/A | 5 | 1 up, 0 down | Nov 14, 2024 | $2.93M |
| Jun 30, 2024 | -$40.60 | -$36.20 | -$42.00 - -$14.60 | -12.15% | Miss | N/A | 6 | 0 up, 0 down | Aug 1, 2024 | $2.55M |
| Mar 31, 2024 | -$41.00 | -$42.44 | -$43.80 - -$41.60 | +3.39% | Beat | N/A | 5 | 0 up, 0 down | May 7, 2024 | $2.09M |
| Dec 31, 2023 | -$40.60 | -$43.93 | -$46.40 - -$33.60 | +7.58% | Beat | N/A | 5 | 0 up, 0 down | Feb 8, 2024 | $2.70M |
| Sep 30, 2023 | -$42.60 | -$47.15 | -$56.00 - -$40.00 | +9.65% | Beat | N/A | 5 | 0 up, 0 down | Nov 2, 2023 | $2.83M |
| Jun 30, 2023 | -$48.00 | -$47.00 | -$52.00 - -$40.00 | -2.13% | Miss | N/A | 5 | 1 up, 0 down | Aug 3, 2023 | $2.20M |
| Mar 31, 2023 | -$48.00 | -$43.00 | -$48.00 - -$32.00 | -11.63% | Miss | N/A | 5 | 0 up, 0 down | May 4, 2023 | $2.30M |
| Dec 31, 2022 | -$0.12 | -$0.13 | -$0.14 - -$0.10 | +7.69% | Beat | N/A | 5 | 0 up, 0 down | Mar 13, 2023 | $2.89M |
| Sep 30, 2022 | -$56.00 | -$68.00 | -$68.00 - -$60.00 | +17.65% | Beat | N/A | 5 | 0 up, 0 down | Nov 9, 2022 | $2.83M |
| Jun 30, 2022 | -$68.00 | -$66.00 | -$68.00 - -$64.00 | -3.03% | Miss | N/A | 5 | 0 up, 0 down | Aug 4, 2022 | $2.39M |
| Mar 31, 2022 | -$72.00 | -$64.00 | -$68.00 - -$60.00 | -12.50% | Miss | N/A | 6 | 0 up, 0 down | May 5, 2022 | $2.06M |
| Dec 31, 2021 | -$0.15 | -$0.13 | -$0.13 - -$0.12 | -15.38% | Miss | N/A | 6 | 0 up, 0 down | Feb 24, 2022 | $3.13M |
| Sep 30, 2021 | -$48.00 | -$52.00 | -$52.00 - -$48.00 | +7.69% | Beat | N/A | 4 | 0 up, 0 down | Nov 9, 2021 | $3.04M |
| Jun 30, 2021 | -$48.00 | -$44.00 | -$44.00 - -$44.00 | -9.09% | Miss | N/A | 5 | N/A | Aug 3, 2021 | $2.29M |
| Mar 31, 2021 | -$44.00 | -$37.00 | N/A | -18.92% | Miss | N/A | 4 | N/A | May 12, 2021 | $2.19M |
| Dec 31, 2020 | -$0.11 | -$0.09 | -$0.12 - -$0.07 | -22.22% | Miss | N/A | 4 | N/A | Mar 16, 2021 | $3.02M |
| Sep 30, 2020 | -$44.00 | -$68.00 | -$68.00 - -$36.00 | +35.29% | Beat | N/A | 3 | N/A | Nov 10, 2020 | $2.74M |
| Jun 30, 2020 | -$68.00 | -$80.00 | -$80.00 - -$64.00 | +15.00% | Beat | N/A | 3 | N/A | Aug 4, 2020 | $2.36M |
| Mar 31, 2020 | -$0.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2020 | $2.71M |
| Dec 31, 2019 | -$5.20 | -$4.00 | N/A | -30.00% | Miss | N/A | N/A | N/A | Mar 19, 2020 | $3.29M |
| Sep 30, 2019 | -$3.80 | -$4.00 | N/A | +5.00% | Beat | N/A | N/A | N/A | Nov 5, 2019 | $2.86M |
| Jun 30, 2019 | -$4.40 | -$3.80 | N/A | -15.79% | Miss | N/A | N/A | N/A | Aug 6, 2019 | $2.09M |
| Mar 31, 2019 | -$6.00 | -$0.19 | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2019 | $1.77M |
| Dec 31, 2018 | -$72.00 | -$84.00 | -$84.00 - -$84.00 | +14.29% | Beat | N/A | 1 | N/A | Mar 26, 2019 | $2.75M |
| Sep 30, 2018 | -$88.00 | -$122.67 | -$176.00 - -$96.00 | +28.26% | Beat | N/A | 4 | N/A | Nov 1, 2018 | $2.85M |
| Jun 30, 2018 | -$104.00 | -$153.33 | -$172.00 - -$128.00 | +32.17% | Beat | N/A | 4 | N/A | Aug 2, 2018 | $2.36M |
| Mar 31, 2018 | -$140.00 | -$140.00 | N/A | 0.00% | In line | N/A | 3 | N/A | May 3, 2018 | $2.47M |
| Dec 31, 2017 | -$0.25 | -$0.45 | -$0.50 - -$0.40 | +44.44% | Beat | N/A | 3 | N/A | Mar 8, 2018 | $3.26M |
| Sep 30, 2017 | -$220.00 | -$186.67 | -$220.00 - -$140.00 | -17.86% | Miss | N/A | 3 | N/A | Nov 7, 2017 | $2.44M |
| Jun 30, 2017 | -$200.00 | -$186.67 | -$220.00 - -$160.00 | -7.14% | Miss | N/A | 3 | N/A | Aug 3, 2017 | $2.06M |
| Mar 31, 2017 | -$220.00 | -$173.33 | N/A | -26.93% | Miss | N/A | N/A | N/A | May 4, 2017 | $2.13M |
| Dec 31, 2016 | -$0.40 | -$0.49 | N/A | +18.37% | Beat | N/A | N/A | N/A | Mar 9, 2017 | $2.36M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$58.35, after -$116.85 the year before. It was -$340.75 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$58.35 | N/A |
| Dec 31, 2024 | -$116.85 | N/A |
| Dec 31, 2023 | -$179.20 | N/A |
| Dec 31, 2022 | -$196.12 | N/A |
| Dec 31, 2021 | -$140.15 | N/A |
| Dec 31, 2020 | -$112.39 | N/A |
| Dec 31, 2019 | -$19.40 | N/A |
| Dec 31, 2018 | -$404.00 | N/A |
| Dec 31, 2017 | -$640.25 | N/A |
| Dec 31, 2016 | -$340.75 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,400 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,391 | 6 | |
| 2026Q1 | Mar 31, 2026 | 2,357 | 8 | |
| 2025Q4 | Dec 31, 2025 | 2,752 | 7 | |
| 2025Q3 | Sep 30, 2025 | 2,346 | 7 | |
| 2025Q2 | Jun 30, 2025 | 4,201 | 11 | |
| 2025Q1 | Mar 31, 2025 | 2,454 | 8 | |
| 2024Q3 | Sep 30, 2024 | 3,671 | 7 | |
| 2024Q2 | Jun 30, 2024 | 4,000 | 8 |
2026Q3 Earnings Call
Opening remarks
Diantha Duvall Host Thank you, and welcome to Curis' Third Quarter 2026 Business Update Call. Before we begin, I would like to encourage everyone to go to the Investors section of our website at www.curis.com to find our third quarter 2026 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me today are Jim Dentzer, President and Chief Executive Officer; Dr. Jonathan Zung, Chief Development Officer; and Dr. Ahmed Hamdy, Chief Medical Officer. We will also be available for a question-and-answer period at the end of the call. I'd now like to turn the call over to Jim.
James Dentzer President and Chief Executive Officer Thank you, Diantha. Good afternoon, everyone, and welcome to Curis' third quarter business update call. I'll start with PCNSL, our lead program and first NHL study. We continue to make steady progress in our TakeAim Lymphoma Study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL subtypes. As a reminder, the TakeAim Lymphoma Study is a registrational study of emavusertib in combination with ibrutinib in patients with relapsed/refractory PCNSL. We reported updated data this quarter for 7 BTK-naive patients and 39 salvage-line patients, patients whose disease had progressed while on treatment with a BTK inhibitor. The updated data show an 86% response rate in BTKi-naive patients, with 6 of 7 patients achieving a response. For context, it's important to note that published studies of BTK inhibitors in PCNSL have generally shown response rates of 39% to 67%. Clearly, the combination of emavusertib plus BTKi appears to be better than BTKi alone. For salvage-line patients, those patients whose disease had progressed while taking a BTK inhibitor, the updated data show a 26% response rate, with 10 of 39 patients responding when treated with the emavusertib plus BTKi combination after they had already progressed on BTKi monotherapy. For context, patients who have failed both frontline therapy and BTKi have a very poor prognosis, with many patients proceeding directly to hospice or best supportive care. That emavusertib is helping patients change that story and reverse their disease is very encouraging. In short, the updated data in both BTKi-naive and salvage-line patients provide further evidence of meaningful clinical activity and continue to support the potential for accelerated approval submissions in both the U.S. and Europe. We look forward to completing full enrollment in this registrational study on schedule in 2027.
Frequently Asked Questions About CRIS
When is Curis's next earnings date?
Curis's next earnings report is expected for Mar 17, 2027.
Did CRIS beat earnings estimates last quarter?
Yes. Curis reported EPS of -$1.94 for the quarter ended Sep 30, 2026, above the -$2.29 estimate, a 15.28% surprise.
What EPS do analysts expect from CRIS next quarter?
The consensus EPS estimate for Curis for the quarter ending Dec 31, 2026 is $2.98 from 6 analysts, with estimates from -$1.71 to $12.60.
How often does CRIS beat earnings estimates?
Curis beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -31.63%.
CRIS pages: Overview, Earnings, Forecast, Financials, Competitors